ABBV 3373
Alternative Names: ABBV-3373; Anti-TNF GRM ADC; anti-TNF-GRM-antibody-drug-conjugate-Abbvie; Human anti-TNF GRM ADCLatest Information Update: 14 Oct 2022
At a glance
- Originator AbbVie
- Class Anti-TNF monoclonal antibodies; Antirheumatics; Drug conjugates; Immunoconjugates; Steroids
- Mechanism of Action Glucocorticoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 10 Oct 2022 No development reported - Phase-II for Rheumatoid arthritis in Poland (IV), Puerto Rico (IV), Israel (IV), Netherlands (IV), Hungary (IV) (Abbvie pipeline October 2022)
- 10 Oct 2022 No development reported - Phase-II for Rheumatoid arthritis in USA (IV) (Abbvie pipeline)
- 02 Jun 2021 Pharmacokinetics data from a phase I part of phase IIa trial in Rheumatoid Arthritis presented at the 22nd Annual Congress of the European League Against Rheumatism (EULAR-2021)